Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $32.4 million.

  • Catalyst Pharmaceuticals' Free Cash Flow fell 5532.69% to $32.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $234.5 million, marking a year-over-year increase of 469.78%. This contributed to the annual value of $239.3 million for FY2024, which is 6687.85% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Free Cash Flow stood at $32.4 million for Q3 2025, which was down 5532.69% from $71.3 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Free Cash Flow registered a high of $72.6 million during Q3 2024, and its lowest value of $2.9 million during Q1 2021.
  • In the last 5 years, Catalyst Pharmaceuticals' Free Cash Flow had a median value of $32.4 million in 2025 and averaged $38.0 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 5975.32% in 2021, then soared by 19204.27% in 2022.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Free Cash Flow stood at $19.1 million in 2021, then surged by 109.44% to $40.1 million in 2022, then surged by 38.62% to $55.6 million in 2023, then rose by 27.42% to $70.8 million in 2024, then tumbled by 54.18% to $32.4 million in 2025.
  • Its Free Cash Flow was $32.4 million in Q3 2025, compared to $71.3 million in Q2 2025 and $60.0 million in Q1 2025.